The short-chain fatty acid methoxyacetic acid disrupts endogenous estrogen receptor-α-mediated signaling

Environmental Health Perspectives

Volumn 117, Issue 11, 2009, Pages 1702-1706

  Henley, Derek V ^a   Mueller, Stephanie ^b   Korach, Kenneth S ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Estrogen; Estrogen receptor; Methoxyacetic acid; Short chain fatty acid

Indexed keywords

ACTIN; ENDOCRINE DISRUPTOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; METHOXYACETIC ACID; SHORT CHAIN FATTY ACID;

ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOMEGALOVIRUS; EXPOSURE; EXPRESSION VECTOR; FEMALE; GENE ACTIVATION; GENE EXPRESSION REGULATION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION;

ACETIC ACIDS; ANIMALS; CELL LINE, TUMOR; CYTOMEGALOVIRUS; ENDOCRINE DISRUPTORS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; MICE; MICE, INBRED C57BL; PROMOTER REGIONS, GENETIC; RESEARCH DESIGN; SIGNAL TRANSDUCTION; UTERUS;

CYTOMEGALOVIRUS;

EID: 75149136733     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.0900800     Document Type: Article

References (32)

1. Abe M, Kufe DW. 1984. Effect of sodium butyrate on human breast carcinoma (MCF7) cellular proliferation, morphology, and CEA production. Breast Cancer Res Treat 4(4):269-274.
2. Bagchi G, Hurst CH, Waxman DJ. 2009. Interactions of methoxyacetic acid with androgen receptor. Toxicol Appl Pharmacol 238(2):101-110.
3. Bjornstrom L, Sjoberg M. 2005. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19(4):833-842.
4. Boffa LC, Vidali G, Mann RS, Allfrey VG. 1978. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem 253(10):3364-3366.
5. Chen G, Yuan PX, Jiang YM, Huang LD, Manji HK. 1999. Valproate robustly enhances AP1 mediated gene expression. Brain Res Mol Brain Res 64(1):52-58.
6. Correa A, Gray RH, Cohen R, Rothman N, Shah F, Seacat H, et al. 1996. Ethylene glycol ethers and risks of spontaneous abortion and subfertility. Am J Epidemiol 143(7):707-717.
7. Davis BJ, Almekinder JL, Flagler N, Travlos G, Wilson R, Maronpot RR. 1997. Ovarian luteal cell toxicity of ethylene glycol monomethyl ether and methoxy acetic acid in vivo and in vitro. Toxicol Appl Pharmacol 142(2):328-337.
8. De los Santos M, MartinezIglesias O, Aranda A. 2007. Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells. Endocr Relat Cancer 14(4):1021-1028.
9. Deroo BJ, Hewitt SC, Peddada SD, Korach KS. 2004. Estradiol regulates the thioredoxin antioxidant system in the mouse uterus. Endocrinology 145(12):5485-5492.
10. Dion LD, Goldsmith KT, Tang DC, Engler JA, Yoshida M, Garver RI Jr. 1997. Amplification of recombinant adenoviral transgene products occurs by inhibition of histone deacetylase. Virology 231(2):201-209.
11. Foster PM, Creasy DM, Foster JR, Gray TJ. 1984. Testicular toxicity produced by ethylene glycol monomethyl and monoethyl ethers in the rat. Environ Health Perspect 57:207-217.
12. Gargas ML, Tyler TR, Sweeney LM, Corley RA, Weitz KK, MastTJ, et al. 2000. A toxicokinetic study of inhaled ethylene glycol monomethyl ether (2ME) and validation of a physiologically based pharmacokinetic model for the pregnant rat and human. Toxicol Appl Pharmacol 165(1):53-62.
13. Gorman CM, Howard BH, Reeves R. 1983. Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res 11(21):7631-7648.
14. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, GiavaraS, et al. 2001. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20(24):6969-6978.
15. Hewitt SC, Harrell JC, Korach KS. 2005. Lessons in estrogen biology from knockout and transgenic animals. Annu Rev Physiol 67:285-308.
16. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV. 1993. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 329(19):1383-1388.
17. Jansen MS, Nagel SC, Miranda PJ, Lobenhofer EK, AfshariCA, McDonnell DP. 2004. Shortchain fatty acids enhance nuclear receptor activity through mitogenactivated protein kinase activation and histone deacetylase inhibition. Proc Natl Acad Sci USA 101(18):7199-7204.
18. Jung JW, Cho SD, Ahn NS, Yang SR, Park JS, Jo EH, et al. 2005. Ras/MAP kinase pathways are involved in Ras specific apoptosis induced by sodium butyrate. Cancer Lett 225(2):199-206.
19. Lofgren E, Mikkonen K, Tolonen U, Pakarinen A, Koivunen R, MyllylaVV, et al. 2007. Reproductive endocrine function in women with epilepsy: the role of epilepsy type and medication. Epilepsy Behav 10(1):77-83.
20. Michaelis M, Suhan T, Michaelis UR, Beek K, Rothweiler F, TauschL, et al. 2006. Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells. Cell Death Differ 13(3):446-453.
21. Miller RR, Hermann EA, Langvardt PW, McKenna MJ, SchwetzBA. 1983. Comparative metabolism and disposition of ethylene glycol monomethyl ether and propylene glycol monomethyl ether in male rats. Toxicol Appl Pharmacol 67(2):229-237.
22. O'Donovan C, Kusumakar V, Graves GR, Bird DC. 2002. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 63(4):322-330.
23. Olsen CM, MeussenElholm ET, Roste LS, Tauboll E. 2004. Antiepileptic drugs inhibit cell growth in the human breast cancer cell line MCF7. Mol Cell Endocrinol 213(2):173-179.
24. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, KleinPS. 2001. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276(39):36734-36741.
25. Rao PN. 1971. Preparation of 9alpha,11xitritiated 17alphaethynylestradiol, mestranol, estradiolalpha17beta, and norethindrone. Steroids 18(2):219-229.
26. Reid G, Metivier R, Lin CY, Denger S, Ibberson D, Ivacevic T, et al. 2005. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene 24(31):4894-4907.
27. Rivero JA, Adunyah SE. 1996. Sodium butyrate induces tyrosine phosphorylation and activation of MAP kinase (ERK-1) in human K562 cells. Biochem Biophys Res Commun 224(3):796-801.
28. Sealy L, Chalkley R. 1978. The effect of sodium butyrate on histone modification. Cell 14(1):115-121.
29. Stevens MS, Aliabadi Z, Moore MR. 1984. Associated effects of sodium butyrate on histone acetylation and estrogen receptor in the human breast cancer cell line MCF7. Biochem Biophys Res Commun 119(1):132-138.
30. Welch LS, Schrader SM, Turner TW, Cullen MR. 1988. Effects of exposure to ethylene glycol ethers on shipyard painters: II. Male reproduction. Am J Ind Med 14(5):509-526.
31. Welsch F. 2005. The mechanism of ethylene glycol ether reproductive and developmental toxicity and evidence for adverse effects in humans. Toxicol Lett 156(1):13-28.
32. Witt O, Monkemeyer S, Kanbach K, Pekrun A. 2002. Induction of fetal hemoglobin synthesis by valproate: modulation of MAP kinase pathways. Am J Hematol 71(1):45-46.